NEW YORK—Maryland-based MMG, which specializes in patient enrollment for clinical trials, will join the Ketchum network, operating as a distinct business unit within the group. The two companies, both owned by Omnicom Group, will retain their respective brand identities and office locations.
Together, the two firms will provide a diverse set of services. MMG's in-depth understanding of the clinical trial business will add to Ketchum's healthcare offering and improve its ability to provide healthcare clients with communication services in the earliest phase of a product’s lifecycle. Ketchum’s global team of pharmaceutical, consumer healthcare, provider relations, advocacy relations, and media and new media experts will provide additional depth to MMG's service offerings while Ketchum's network, which includes operations in more than 50 international markets, strengthens MMG's global service offerings as the need for patient recruitment continues to grow outside of the U.S.
“As science and technology continue to converge in new and exciting ways, the healthcare industry faces numerous global opportunities. This combination demonstrates Ketchum's and MMG's commitment to help healthcare organizations maximize the opportunities and minimize the challenges ahead,” says Ketchum senior partner Lorraine Thelian. “Matching Ketchum's communications expertise with MMG's focus on clinical trials will help clients identify and communicate valuable healthcare information about diseases and potential treatments to diverse global patient, physician and advocacy audiences.”
MMG is headed by John Benbrook, CEO, and a seven-member executive committee, which will all continue to report directly to Benbrook.